For: | Onat A, Aydın M, Can G, Çakmak HA, Köroğlu B, Kaya A, Ademoğlu E. Impaired fasting glucose: Pro-diabetic, “atheroprotective” and modified by metabolic syndrome. World J Diabetes 2013; 4(5): 210-218 [PMID: 24147205 DOI: 10.4239/wjd.v4.i5.210] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v4/i5/210.htm |
Number | Citing Articles |
1 |
María Teresa Martínez-Larrad, Arturo Corbatón-Anchuelo, Cristina Fernández-Pérez, Yera Lazcano-Redondo, Fernando Escobar-Jiménez, Manuel Serrano-Ríos. Metabolic syndrome, glucose tolerance categories and the cardiovascular risk in Spanish population. Diabetes Research and Clinical Practice 2016; 114: 23 doi: 10.1016/j.diabres.2016.02.003
|
2 |
Bernd Richter, Bianca Hemmingsen, Maria-Inti Metzendorf, Yemisi Takwoingi. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database of Systematic Reviews 2018; 2018(11) doi: 10.1002/14651858.CD012661.pub2
|
3 |
Bermúdez Valmore, Rojas Joselyn, Salazar Juan, González Robys, Martínez María Sofía, Chávez Carmen, Palacio Marcos, Rojas Edward, Cabrera Mayela, Miranda José López. Coronary Risk Estimation according to the Framingham-Wilson Score and Impaired Fasting Glucose in Adult Subjects from Maracaibo city, Venezuela. Global Journal of Obesity, Diabetes and Metabolic Syndrome 2014; 1(1): 020 doi: 10.17352/2455-8583.000004
|
4 |
Altan Onat, Günay Can, Ayşem Kaya, Tuğba Akbaş, Fatma Özpamuk-Karadeniz, Barış Şimşek, Hakan Çakır, Hüsniye Yüksel. Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality. World Journal of Gastroenterology 2015; 21(48): 13555-13565 doi: 10.3748/wjg.v21.i48.13555
|
5 |
Altan Onat, Mesut Aydın, Günay Can, Etem Çelik, Servet Altay, Ahmet Karagöz, Evin Ademoğlu. Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk. Endocrine 2015; 48(1): 218 doi: 10.1007/s12020-014-0269-z
|
6 |
Servet Altay, Altan Onat, Yusuf Karadeniz, Fatma Özpamuk-Karadeniz, Günay Can. Prediction by Low Plasma HbA1c of Mortality, Cardiac and Noncardiac Disease Risk: Modulation by Diabetic Status and Sex. Journal of Investigative Medicine 2015; 63(6): 821 doi: 10.1097/JIM.0000000000000216
|
7 |
Günay Can, Altan Onat, Eray Yurtseven, Yusuf Karadeniz, Tuğba Akbaş-Şimşek, Ayşem Kaya, Hüsniye Yüksel. Gender-modulated risk of coronary heart disease, diabetes and coronary mortality among Turks for three major risk factors, and residual adiposity risk. BMC Endocrine Disorders 2016; 16(1) doi: 10.1186/s12902-016-0134-6
|
8 |
Altan Onat, İbrahim Dönmez, Yusuf Karadeniz, Hakan Çakır, Ayşem Kaya. Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity. Expert Review of Cardiovascular Therapy 2014; 12(6): 667 doi: 10.1586/14779072.2014.910114
|
9 |
M A Hajebrahimi, S Akbarpour, A Eslami, F Azizi, F Hadaegh. Different combinations of glucose tolerance and blood pressure status and incident cardiovascular disease and all-cause mortality events. Journal of Human Hypertension 2017; 31(11): 744 doi: 10.1038/jhh.2017.49
|
10 |
Yusuf Olgar, Erkan Tuncay, Deniz Billur, Belma Turan. Bimodal Effects of P2Y12 Antagonism on Matrix Metalloproteinase–Associated Contractile Dysfunction in İnsulin-Resistant Mammalian Heart. Biological Trace Element Research 2022; 200(5): 2195 doi: 10.1007/s12011-021-02816-w
|
11 |
Barış Şimşek, Servet Altay, Nazmiye Özbilgin, Altan Onat. Autoimmune activation as a determinant of atrial fibrillation among Turks. Medicine 2018; 97(31): e11779 doi: 10.1097/MD.0000000000011779
|